Clients will gain insight into the percentage of cancer patients treated with biosimilars, the price of these agents compared to their originator, and key opinion leaders’ outlook for the products. The report includes the 8MM regulatory landscapes, their market potential, and their available and upcoming biosimilars. Additionally, the report includes the opportunities and challenges facing biosimilar uptake and a commercial assessment of the major players in the field. The report is supplemented with insight from four key opinion leaders, one payer, and 103 high-prescribing physicians surveyed in the 8MM.
The biosimilar market has increased sharply in the last five years, and the publsiher projects moderately high future growth at a compound annual growth rate (CAGR) of 9.1%
The biosimilar market has increased sharply in the last five years, and the publsiher projects moderately high future growth at a compound annual growth rate (CAGR) of 9.1%
- Europe leads the way for oncology biosimilars in the 8MM. China is at the forefront in the emerging markets
- Pricing is a key issue for biosimilars entering an increasingly crowded market
- Sandoz and Amgen are main players in the development of biosimilars in oncology
Key Highlights
- Report deliverables include a PowerPoint report
- Survey & Clinical trial analysis includes 8 countries
- 4 KOLs and one payer interviewed
Scope
Contents include -- Biosimilars in oncology overview
- Trends
- Value chain
- Leading marketed and pipeline products
- Market analysis
- Regulatory landscape and market access
- Opportunities and unmet needs
- Commercial assessment - major current and future players in the biosimilar field
Reasons to Buy
- OBTAIN Biosimilars in oncology MARKET ASSESSMENT ACROSS MULTIPLE REGIONS
- GAIN INSIGHT INTO APPROACHES REQUIRED TO PROMOTE BIOSIMILAR UPTAKE
The thematic reports answer questions such as:
- What is the percentage of cancer patients treated with biosimilars in each 8MM country?
- Which patient groups are more likely to receive these therapies?
- What is the price of these agents compared to their originator molecule?
- What is the key opinion leaders’ outlook for the products?
- How do biosimilar discounts work and how might they affect future uptake?
Table of Contents
1. Executive Summary11. Appendix12. Contact the Publisher
2. Biosimilars in Oncology Overview
3. Value Chain
4. Trends
5. Market Analysis
6. Marketed Products
7. Pipeline Products
8. Regulatory
9. Opportunities, Challenges and Unmet Needs
10. Companies
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Co
- Sanofi
- Amgen Inc
- Sandoz
- Celltrion
- Biocon
- Pfizer
- Organon
- Regeneron
- Merck & Co
